Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature

Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.

Detalles Bibliográficos
Autores principales: Win, Hninyee, Gowin, Krisstina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752349/
https://www.ncbi.nlm.nih.gov/pubmed/33363876
http://dx.doi.org/10.1002/ccr3.3302
_version_ 1783625842788663296
author Win, Hninyee
Gowin, Krisstina
author_facet Win, Hninyee
Gowin, Krisstina
author_sort Win, Hninyee
collection PubMed
description Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease.
format Online
Article
Text
id pubmed-7752349
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77523492020-12-23 Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature Win, Hninyee Gowin, Krisstina Clin Case Rep Case Reports Scleromyxedema is a rare and progressive disease that currently has no standard treatment. Triplet therapy with lenalidomide, bortezomib, and dexamethasone can be an effective therapy for scleromyxedema, especially in patients with refractory or relapsed disease. John Wiley and Sons Inc. 2020-09-17 /pmc/articles/PMC7752349/ /pubmed/33363876 http://dx.doi.org/10.1002/ccr3.3302 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Win, Hninyee
Gowin, Krisstina
Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
title Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
title_full Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
title_fullStr Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
title_full_unstemmed Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
title_short Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature
title_sort treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: a case report and review of the literature
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752349/
https://www.ncbi.nlm.nih.gov/pubmed/33363876
http://dx.doi.org/10.1002/ccr3.3302
work_keys_str_mv AT winhninyee treatmentofscleromyxedemawithlenalidomidebortezomibanddexamethasoneacasereportandreviewoftheliterature
AT gowinkrisstina treatmentofscleromyxedemawithlenalidomidebortezomibanddexamethasoneacasereportandreviewoftheliterature

Ejemplares similares